Skip to main content
. 2019 Oct 4;10:790. doi: 10.3389/fgene.2019.00790

Figure 5.

Figure 5

Comparison on cell viabilities in response to Tamoxifen, Doxirubicin, and combined use of Tamoxifen and Doxirubicin among different cell lines. Drug response curves under the treatment of (A) Tamoxifen, (B) Doxirubicin, (C) combined used of Tamoxifen and 10 nm Doxirubicin, and (D) combined use of Tamoxifen and IC50 Doxirubicin. AdKu-231 was used in this figure.